{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:58:21Z","timestamp":1792979901527,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["TMA2019CDF-2670"],"award-info":[{"award-number":["TMA2019CDF-2670"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"DOI":"10.1186\/s12981-025-00787-9","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T06:49:57Z","timestamp":1756536597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Drug-drug interaction between dolutegravir and artemether-lumefantrine in HIV and malaria mono- and co-infections: a pharmacogenetic analysis from Ghana"],"prefix":"10.1186","volume":"22","author":[{"given":"Nicholas Ekow","family":"Thomford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Kellermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel Adu","family":"Twum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Anyimadu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charn\u00e9","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Sappor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dee","family":"Blackhurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prince Amoah","family":"Barnie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oksana","family":"Ryabinina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Badu","family":"Nyarko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Peter","family":"Biney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martins","family":"Ekor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George B.","family":"Kyei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"issue":"3","key":"787_CR1","doi-asserted-by":"publisher","first-page":"e214","DOI":"10.1016\/S2666-5247(24)00016-8","volume":"5","author":"P Venkatesan","year":"2024","unstructured":"Venkatesan P. The 2023 WHO world malaria report. Lancet Microbe. 2024;5(3):e214.","journal-title":"Lancet Microbe"},{"key":"787_CR2","unstructured":"HIV. [https:\/\/www.who.int\/data\/gho\/data\/themes\/hiv-aids"},{"issue":"9","key":"787_CR3","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1097\/00006454-199709000-00011","volume":"16","author":"I Kalyesubula","year":"1997","unstructured":"Kalyesubula I, Musoke-Mudido P, Marum L, Bagenda D, Aceng E, Ndugwa C, Olness K. Effects of malaria infection in human immunodeficiency virus type 1-infected Ugandan children. Pediatr Infect Dis J. 1997;16(9):876\u201381.","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"787_CR4","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1093\/ije\/27.2.296","volume":"27","author":"D Chandramohan","year":"1998","unstructured":"Chandramohan D, Greenwood BM. Is there an interaction between human immunodeficiency virus and plasmodium falciparum? Int J Epidemiol. 1998;27(2):296\u2013301.","journal-title":"Int J Epidemiol"},{"issue":"2","key":"787_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJM199107113250206","volume":"325","author":"AE Greenberg","year":"1991","unstructured":"Greenberg AE, Nsa W, Ryder RW, Medi M, Nzeza M, Kitadi N, Baangi M, Malanda N, Davachi F, Hassig SE. Plasmodium falciparum malaria and perinatally acquired human immunodeficiency virus type 1 infection in kinshasa, zaire. A prospective, longitudinal cohort study of 587 children. N Engl J Med. 1991;325(2):105\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"787_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4269\/ajtmh.2012.11-0380","volume":"87","author":"ET Nkhoma","year":"2012","unstructured":"Nkhoma ET, Kalilani-Phiri L, Mwapasa V, Rogerson SJ, Meshnick SR. Effect of HIV infection and plasmodium falciparum parasitemia on pregnancy outcomes in Malawi. Am J Trop Med Hyg. 2012;87(1):29\u201334.","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"787_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1086\/505087","volume":"194","author":"SR Meshnick","year":"2006","unstructured":"Meshnick SR, Mwapasa V, Rogerson SJ. Protecting pregnant women from malaria in areas of high HIV infection prevalence. J Infect Dis. 2006;194(3):273\u20135.","journal-title":"J Infect Dis"},{"key":"787_CR8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1186\/s12936-015-1029-0","volume":"14","author":"G Alemayehu","year":"2015","unstructured":"Alemayehu G, Melaku Z, Abreha T, Alemayehu B, Girma S, Tadesse Y, Gadisa T, Lulseged S, Balcha TT, Hoos D, et al. Burden of malaria among adult patients attending general medical outpatient department and HIV care and treatment clinics in oromia, ethiopia: a comparative cross-sectional study. Malar J. 2015;14:501\u2013501.","journal-title":"Malar J"},{"issue":"18","key":"787_CR9","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1097\/00002030-200112070-00013","volume":"15","author":"P Francesconi","year":"2001","unstructured":"Francesconi P, Fabiani M, Dente MG, Lukwiya M, Okwey R, Ouma J, Ochakachon R, Cian F, Declich S. HIV, malaria parasites, and acute febrile episodes in Ugandan adults: a case-control study. AIDS. 2001;15(18):2445\u201350.","journal-title":"AIDS"},{"issue":"6","key":"787_CR10","doi-asserted-by":"publisher","first-page":"e0129519","DOI":"10.1371\/journal.pone.0129519","volume":"10","author":"M Orlov","year":"2015","unstructured":"Orlov M, Smeaton LM, Kumwenda J, Hosseinipour MC, Campbell TB, Schooley RT. Presence of plasmodium falciparum DNA in plasma does not predict clinical malaria in an HIV-1 infected population. PLoS ONE. 2015;10(6):e0129519.","journal-title":"PLoS ONE"},{"issue":"9455","key":"787_CR11","first-page":"233","volume":"365","author":"JG Kublin","year":"2005","unstructured":"Kublin JG, Patnaik P, Jere CS, Miller WC, Hoffman IF, Chimbiya N, Pendame R, Taylor TE, Molyneux ME. Effect of plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural malawi: a prospective cohort study. Lancet. 2005;365(9455):233\u201340.","journal-title":"Lancet"},{"key":"787_CR12","first-page":"11","volume":"7","author":"HS Kiyingi","year":"2010","unstructured":"Kiyingi HS, Egwang TG, Nannyonga M. Prolonged elevation of viral loads in HIV-1-infected children in a region of intense malaria transmission in Northern uganda: a prospective cohort study. Pan Afr Med J. 2010;7:11.","journal-title":"Pan Afr Med J"},{"issue":"1","key":"787_CR13","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s13071-022-05432-2","volume":"15","author":"S-T Mirzohreh","year":"2022","unstructured":"Mirzohreh S-T, Safarpour H, Pagheh AS, Bangoura B, Barac A, Ahmadpour E. Malaria prevalence in HIV-positive children, pregnant women, and adults: a systematic review and meta-analysis. Parasites Vectors. 2022;15(1):324.","journal-title":"Parasites Vectors"},{"issue":"1","key":"787_CR14","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12884-020-03064-x","volume":"20","author":"P Ssentongo","year":"2020","unstructured":"Ssentongo P, Ba DM, Ssentongo AE, Ericson JE, Wang M, Liao D, Chinchilli VM. Associations of malaria, HIV, and coinfection, with anemia in pregnancy in sub-Saharan africa: a population-based cross-sectional study. BMC Pregnancy Childbirth. 2020;20(1):379.","journal-title":"BMC Pregnancy Childbirth"},{"key":"787_CR15","doi-asserted-by":"crossref","unstructured":"Francis J, Barnes KI, Workman L, Kredo T, Vestergaard LS, Hoglund RM, Byakika-Kibwika P, Lamorde M, Walimbwa SI, Chijioke-Nwauche I et al. An individual participant data population Pharmacokinetic Meta-analysis of Drug-Drug interactions between lumefantrine and commonly used antiretroviral treatment. Antimicrob Agents Chemother 2020, 64(5).","DOI":"10.1128\/AAC.02394-19"},{"issue":"2","key":"787_CR16","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/QAI.0000000000002237","volume":"83","author":"E Hughes","year":"2020","unstructured":"Hughes E, Mwebaza N, Huang L, Kajubi R, Nguyen V, Nyunt MM, Orukan F, Mwima MW, Parikh S, Aweeka F. Efavirenz-Based antiretroviral therapy reduces Artemether-Lumefantrine exposure for malaria treatment in HIV-Infected pregnant women. J Acquir Immune Defic Syndr. 2020;83(2):140\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"787_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12936-024-04930-1","volume":"23","author":"NE Thomford","year":"2024","unstructured":"Thomford NE, Kellermann T, Biney RP, Dixon C, Nyarko SB, Ateko RO, Ekor M, Kyei GB. Therapeutic efficacy of generic artemether-lumefantrine in the treatment of uncomplicated malaria in ghana: assessing anti-malarial efficacy amidst Pharmacogenetic variations. Malar J. 2024;23(1):125.","journal-title":"Malar J"},{"issue":"7","key":"787_CR18","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1093\/jac\/dkae147","volume":"79","author":"LJ Else","year":"2024","unstructured":"Else LJ, Dickinson L, Edick S, Zyhowski A, Ho K, Meyn L, Dilly-Penchala S, Thompson B, Shaw V, Khoo S, et al. Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed Pharmacokinetic trial to aid point-of-care testing. J Antimicrob Chemother. 2024;79(7):1597\u2013605.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"787_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40121-014-0029-7","volume":"3","author":"DE Dow","year":"2014","unstructured":"Dow DE, Bartlett JA. Dolutegravir, the Second-Generation of integrase strand transfer inhibitors (INSTIs) for the treatment of HIV. Infect Dis Therapy. 2014;3(2):83\u2013102.","journal-title":"Infect Dis Therapy"},{"issue":"7","key":"787_CR20","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1111\/bcp.15683","volume":"89","author":"R Mehta","year":"2023","unstructured":"Mehta R, Lagishetty CV, Angelis K, Aylott A, Kahl L, Blair L, Matthews J, Wynne B, Crauwels H, Underwood M, et al. Pharmacokinetic and pharmacokinetic\/pharmacodynamic characterization of the dolutegravir\/rilpivirine two-drug regimen in SWORD-1\/-2 phase 3 studies. Br J Clin Pharmacol. 2023;89(7):2190\u2013200.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"787_CR21","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1097\/QAD.0000000000003843","volume":"38","author":"D Cattaneo","year":"2024","unstructured":"Cattaneo D, Pagano S, Colombo ML, Giacomelli A, Gori A, Gervasoni C. Different effects of the companion antiretroviral drugs on dolutegravir trough concentrations. Aids. 2024;38(6):847\u201351.","journal-title":"Aids"},{"issue":"4","key":"787_CR22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3851\/IMP3119","volume":"22","author":"D Cattaneo","year":"2017","unstructured":"Cattaneo D, Minisci D, Cozzi V, Riva A, Meraviglia P, Clementi E, Galli M, Gervasoni C. Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect? Antivir Ther. 2017;22(4):353\u20136.","journal-title":"Antivir Ther"},{"issue":"1","key":"787_CR23","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1128\/AAC.00842-09","volume":"54","author":"S Min","year":"2010","unstructured":"Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T, Piscitelli SC. Pharmacokinetics and safety of S\/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010;54(1):254\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"787_CR24","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1186\/1475-2875-8-S1-S4","volume":"8","author":"A Djimd\u00e9","year":"2009","unstructured":"Djimd\u00e9 A, Lef\u00e8vre G. Understanding the pharmacokinetics of Coartem\u00ae. Malar J. 2009;8(1):S4.","journal-title":"Malar J"},{"issue":"1","key":"787_CR25","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.4102\/sajhivmed.v23i1.1435","volume":"23","author":"LA Mandikiyana Chirimuta","year":"2022","unstructured":"Mandikiyana Chirimuta LA, Pascoe MJ, Lowe S. Emergent dolutegravir resistance in integrase-na\u00efve, treatment experienced patients from Zimbabwe. South Afr J HIV Med. 2022;23(1):1435.","journal-title":"South Afr J HIV Med"},{"issue":"1","key":"787_CR26","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/cid\/ciae006","volume":"79","author":"A Ursenbach","year":"2024","unstructured":"Ursenbach A, Ruch Y, Hoellinger B, Fuchs A, Caspar S, Jegou F, Rey D, Fafi-Kremer S, Mespl\u00e8de T, Gantner P. Two cases of viral Re-suppression after M184V\u2009+\u2009R263K selection on dolutegravir\/lamivudine without treatment modification. Clin Infect Dis. 2024;79(1):198\u2013201.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"787_CR27","doi-asserted-by":"publisher","first-page":"e733","DOI":"10.1016\/S2352-3018(23)00228-X","volume":"10","author":"T Loosli","year":"2023","unstructured":"Loosli T, Hossmann S, Ingle SM, Okhai H, Kusejko K, Mouton J, Bellecave P, van Sighem A, Stecher M, d\u2019Arminio Monforte A, et al. HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis. Lancet HIV. 2023;10(11):e733\u201341.","journal-title":"Lancet HIV"},{"issue":"9","key":"787_CR28","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/infdis\/jiac174","volume":"226","author":"Z Cindi","year":"2022","unstructured":"Cindi Z, Kawuma AN, Maartens G, Bradford Y, Venter F, Sokhela S, Chandiwana N, Wasmann RE, Denti P, Wiesner L, et al. Pharmacogenetics of dolutegravir plasma exposure among Southern Africans with human immunodeficiency virus. J Infect Dis. 2022;226(9):1616\u201325.","journal-title":"J Infect Dis"},{"issue":"3","key":"787_CR29","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/QAI.0000000000003358","volume":"95","author":"SA Spector","year":"2024","unstructured":"Spector SA, Brummel SS, Chang A, Wiznia A, Ruel TD, Acosta EP. Impact of genetic variants in ABCG2, NR1I2, and UGT1A1 on the pharmacokinetics of dolutegravir in children. J Acquir Immune Defic Syndr. 2024;95(3):297\u2013303.","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00787-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-025-00787-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00787-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T05:42:38Z","timestamp":1757482958000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-025-00787-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["787"],"URL":"https:\/\/doi.org\/10.1186\/s12981-025-00787-9","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,30]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}